165 related articles for article (PubMed ID: 9373310)
21. "Diabodies": small bivalent and bispecific antibody fragments.
Holliger P; Prospero T; Winter G
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6444-8. PubMed ID: 8341653
[TBL] [Abstract][Full Text] [Related]
22. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
[TBL] [Abstract][Full Text] [Related]
23. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
24. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features.
Harmsen MM; Ruuls RC; Nijman IJ; Niewold TA; Frenken LG; de Geus B
Mol Immunol; 2000 Aug; 37(10):579-90. PubMed ID: 11163394
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of human and mouse immunoglobulin variable heavy regions from IMGT/LIGM-DB with IMGT/HighV-QUEST.
Shi B; Ma L; He X; Wang X; Wang P; Zhou L; Yao X
Theor Biol Med Model; 2014 Jul; 11():30. PubMed ID: 24992938
[TBL] [Abstract][Full Text] [Related]
26. The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen.
Xiang J; Liu E; Delbaere LT; Chen Z; Luo X; Qi Y; Rathgeber C
Cancer Biother; 1993; 8(3):253-62. PubMed ID: 7804366
[TBL] [Abstract][Full Text] [Related]
27. Domain interactions and antigen binding of recombinant anti-Z-DNA antibody variable domains. The role of heavy and light chains measured by surface plasmon resonance.
Polymenis M; Stollar BD
J Immunol; 1995 Mar; 154(5):2198-208. PubMed ID: 7868893
[TBL] [Abstract][Full Text] [Related]
28. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability.
Davies J; Riechmann L
Protein Eng; 1996 Jun; 9(6):531-7. PubMed ID: 8862554
[TBL] [Abstract][Full Text] [Related]
29. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab.
Chatellier J; Van Regenmortel MH; Vernet T; Altschuh D
J Mol Biol; 1996 Nov; 264(1):1-6. PubMed ID: 8950262
[TBL] [Abstract][Full Text] [Related]
30. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops.
Decanniere K; Desmyter A; Lauwereys M; Ghahroudi MA; Muyldermans S; Wyns L
Structure; 1999 Apr; 7(4):361-70. PubMed ID: 10196124
[TBL] [Abstract][Full Text] [Related]
31. Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding.
de Haard HJ; Kazemier B; van der Bent A; Oudshoorn P; Boender P; van Gemen B; Arends JW; Hoogenboom HR
Protein Eng; 1998 Dec; 11(12):1267-76. PubMed ID: 9930677
[TBL] [Abstract][Full Text] [Related]
32. Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies.
Rouet R; Dudgeon K; Christie M; Langley D; Christ D
J Biol Chem; 2015 May; 290(19):11905-17. PubMed ID: 25737448
[TBL] [Abstract][Full Text] [Related]
33. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme.
Desmyter A; Transue TR; Ghahroudi MA; Thi MH; Poortmans F; Hamers R; Muyldermans S; Wyns L
Nat Struct Biol; 1996 Sep; 3(9):803-11. PubMed ID: 8784355
[TBL] [Abstract][Full Text] [Related]
35. The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3.
Li Y; Spellerberg MB; Stevenson FK; Capra JD; Potter KN
J Mol Biol; 1996 Mar; 256(3):577-89. PubMed ID: 8604140
[TBL] [Abstract][Full Text] [Related]
36. Single domain camel antibodies: current status.
Muyldermans S
J Biotechnol; 2001 Jun; 74(4):277-302. PubMed ID: 11526908
[TBL] [Abstract][Full Text] [Related]
37. Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen.
Chen C; Roberts VA; Rittenberg MB
J Exp Med; 1992 Sep; 176(3):855-66. PubMed ID: 1512548
[TBL] [Abstract][Full Text] [Related]
38. Antigen-binding specificities of antibodies are primarily determined by seven residues of VH.
Ohno S; Mori N; Matsunaga T
Proc Natl Acad Sci U S A; 1985 May; 82(9):2945-9. PubMed ID: 3921967
[TBL] [Abstract][Full Text] [Related]
39. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries.
Kim HS; Lo SC; Wear DJ; Stojadinovic A; Weina PJ; Izadjoo MJ
J Immunol Methods; 2011 Sep; 372(1-2):146-61. PubMed ID: 21787781
[TBL] [Abstract][Full Text] [Related]
40. A functional antibody mutant with an insertion in the framework region 3 loop of the VH domain: implications for antibody engineering.
Simon T; Rajewsky K
Protein Eng; 1992 Apr; 5(3):229-34. PubMed ID: 1409542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
